Evidence map›Paper›PMID 37250533›Full record

ArticlePakistan journal of medical sciences

Copy number variations and protein expression of Cyclin E1 and Epithelial cell transforming sequence 2 genes predict the chemotherapeutic response in patients with serous ovarian carcinoma.

Rahat Sarfraz, Atika Masood, Saima Zaki, Amira Shami, Saba Khaliq, Nadia Naseem

Open access · goldAbstract read
In one paragraph

Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rahat SarfrazRahat Sarfraz, Department of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan.
Atika MasoodAtika Masood, Department of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan.
Saima ZakiSaima Zaki, Associate Professor, Department of Obstetrics & Gynaecology, Jinnah Hospital, Lahore, Pakistan.
Amira ShamiAmira Shami, Consultant Oncologist, Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
Saba KhaliqSaba Khaliq, Associate Professor, Department of Physiology & Cell Biology, University of Health Sciences, Lahore, Pakistan.
Nadia NaseemNadia Naseem, Professor & Head, Department of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan.
University of Health Sciences Lahore · PKMarymount University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Objectives: Serous ovarian carcinoma (SOC) is characterized by extreme genomic instability, chromosomal rearrangements and copy number variations (CNVs) leading to the development of early metastasis and chemo-resistance. The present study was designed to observe the role of CNVs of Cyclin E1 (CCNE1) and Epithelial cell transforming sequence- 2 Methods: This observational analytical study was conducted at University of Health Sciences, Lahore, Pakistan from December 2019 till June 2022.The study included twenty-five SOC patients with resectable ovarian tumors and twenty-five control subjects. The patients were followed-up for six months for their response to chemotherapy. The CNVs in Results: The copy number variations in Conclusion: The copy number variations of

Indexed as

Chemotherapy responseCopy number variantsCyclin E1 geneEpithelial cell transforming sequence 2 geneSerous Ovarian Carcinoma

Identifiers

PMID37250533
PMCPMC10214807
OpenAlexW4361217119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.